The FDA Office of Women’s Health (OWH) was established by congressional mandate to advocate for the participation of women in clinical trials and the analyses of data by sex. OWH supports studies to track the participation of women in clinical trials and collaborates with FDA centers and external partners to understand sex and gender differences in disease prevalence and response to therapy through science and research.
- Adequate participation of women in clinical trials allows representation of the population most likely to use a disease therapy.
- Analyzing data by sex allows researchers to determine if there are any sex differences in a disease therapy.
- Sex differences can include differences in disease prevalence and response.
- Analyses for sex differences can provide insight into the scientific basis for individual therapy differences and provide future directions for research.
Check the links on this page to learn more about OWH activities and other resources related to women in clinical trials.
Conference: Dialogues on Diversifying Clinical Trials: Successful Strategies for Engaging Women and Minorities, September 22-23, 2011, Washington, DC (Held in Collaboration with the Society for Women’s Health Research)
Workshop: Exploration of Public Policy Development Regarding the Study and Analysis of Sex Differences in the Clinical Evaluation of Cardiovascular Medical Products, June 2, 2008, Kathryn M. O’Callaghan, B.S., CDRH
Workshop: Gender Differences in Cardiovascular Device Trials, December 9, 2008, Kathryn M. O’Callaghan, B.S., CDRH
Workshop: Gender Studies in Product Development: Scientific Issues and Approaches. November 1995
Individual patient-data meta-analysis and postmarket analysis as a method for improving data quality in demographic subgroups (Support for implementation of FDASIA Section 907 Action Plan- Daniel Canos, PhD/CDRH (15)
Evaluation of gender-related clinical pharmacology information in the labelings on adverse events and outcomes. Lei Zhang, PhD, CDER (2010)
Identification of Sex Differences in Adverse Outcomes for New Molecular Entities (NMEs) Approved from 2000-2002. Yongsheng Yang, Ph.D., CDER (2007)
Participation of Women in Clinical Trials and Gender Analysis of Data in Original NDAs Approved 2000-2002. Yongsheng Yang, Ph.D., CDER (2006)
Gender Differences and Impact of Pharmacogenomics in Rheumatoid Arthritis. Shashi Amur Ph.D., CDER (2006)
Impact of Gender Analysis and Pharmacogenomics on Clinical Efficacy, Safety, and Pharmacokinetics of Drugs Used for the Treatment of Alzheimer’s Disease. Angela Men, Ph.D., CDER (2006)
Women in HIV Trials: A Comprehensive Review and Meta-Analysis. Greg Soon, Ph.D., CDER (2006)
Statistical Analysis of Gender Specific Data from New Drug Application (NDA) Submissions. Ohidul Siddiqui Ph.D., CDER (2006)
Evaluation of Availability and Quality of Information Available on Females Included in Mechanical Device Implant Trials. Kathryn O’Callaghan B.S., CDRH (2006)
Women’s participation in clinical drug trials for unstable angina and myocardial infarction. Ann Farrell, MD, CDER (2000)
Development and expansion of a pilot tracking system for monitoring the barriers to the enrollment of women in clinical trials. Toigo, Teresa, RPH, MBA, OC/OEA (1995)
- Successful Strategies for Engaging Women and Minorities in Clinical Trials (PDF - 1.2MB)
- Outreach Toolkit: How to Engage, Recruit, and Retain Women in Clinical Research (NIH Office of Research on Women's Health)
- Inclusion of Women in Research (NIH Office of Research on Women's Health)